Bio-Path Holdings Reports Third Quarter 2024 Financial Results

Expands DNAbilize® Technology Beyond Oncology into Obesity

Conference Call to be Held Today at 8:30 A.M. ET

HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2024 and provided an update on recent corporate developments.

Read more at globenewswire.com